Jennifer M. Streit, BS, MT(ASCP)

Surveillance Manager
JMI Laboratories

Disclosure(s): Cidara: Grant/Research Support; GSK: Grant/Research Support; Melinta: Grant/Research Support; Shionogi: Grant/Research Support

Poster(s):

124 - Activity of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations Against AmpC-Producing Species Collected in United States Hospitals
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
641 - Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
642 - In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020-2021)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
643 - Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020-2021)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
645 - Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014-2021
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
646 - Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
660 - In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
1675 - Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1734 - Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
2044 - In Vitro Activity of Omadacycline Against 14,000 Bacterial Isolates from the United States by Infection Type (2020-2021)
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
2176 - In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET